Novavax, Inc. (NVAX) vs Viridian Therapeutics, Inc. (VRDN)
- Novavax, Inc. NVAX 11.26 −12.17%
- Viridian Therapeutics, Inc. VRDN 19.03 −2.71%
Novavax, Inc. and Viridian Therapeutics, Inc. are both Biotechnology companies. Novavax, Inc. and Viridian Therapeutics, Inc. are of similar size ($2.2B and $2.1B). Viridian Therapeutics, Inc. grew revenue faster over the last twelve months: 23,220.3% against −61.6%. Novavax, Inc. has the higher net margin (−59.9% vs −544.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Novavax, Inc. leads on 12 and Viridian Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | NVAX | VRDN | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.60% | 100.00% | 65.16% |
| Operating margin | (56.58%) | (569.68%) | 0.00% |
| Net margin | (59.87%) | (544.06%) | 0.00% |
| Free cash flow margin | (10.20%) | (471.04%) | 0.00% |
| Return on equity | 323.66% | (86.93%) | (56.36%) |
| Return on assets | (21.62%) | (46.08%) | (48.04%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack